Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.


Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge
U.S. Praises Kurdistan's Role in Oil Markets Amid Iran War Fallout
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling
France's 2025 Budget Deficit Shrinks More Than Expected, Easing Fiscal Pressure
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Asian Stocks Rebound as Trump Delays Iran Strike Deadline
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes
Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 



